The obesity medicine field has been closely watching retatrutide — commonly referred to as reta in patient communities — since its Phase 2 results turned heads in 2023. Now, Phase 3 data from the TRIUMPH-4 trial has arrived, and the numbers are unlike anything previously recorded in a randomized controlled trial for weight management.
Published via Eli Lilly press release in December 2025, TRIUMPH-4 evaluated retatrutide over a 68-week treatment period at doses of 9mg and 12mg once weekly. The headline finding: participants receiving the 12mg dose achieved a mean weight loss of 28.7% — the highest mean weight reduction ever reported in a Phase 3 obesity trial. To put that in perspective, semaglutide's landmark STEP-1 trial (also 68 weeks) demonstrated approximately 14.9% mean weight loss at its highest dose, while tirzepatide's SURMOUNT-1 trial showed 20.9% mean weight loss at 15mg. Retatrutide at 12mg outpaced both by a substantial margin.
The TRIUMPH-4 titration schedule was carefully structured to manage tolerability:
Discontinuation rates in TRIUMPH-4 were higher in the active treatment arms — 18.2% at 12mg and 12.2% at 9mg compared to 4.0% in the placebo group. Notably, some discontinuations were attributed to perceived excessive weight loss, an observation that underscores the potency of this mechanism. Dysesthesia — an abnormal skin sensation — was reported in 20.9% of participants at 12mg versus 0.7% on placebo, a signal that was also observed in Phase 2 data and one that clinicians will continue to monitor carefully. Full peer-reviewed Phase 3 publication remains pending as of April 2026.
| Medication | Trial | Duration | Highest Dose Tested | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide | STEP-1 | 68 weeks | 2.4mg weekly | ~14.9% |
| Tirzepatide | SURMOUNT-1 | 72 weeks | 15mg weekly | 20.9% |
| Retatrutide | TRIUMPH-4 (Phase 3) | 68 weeks | 12mg weekly | 28.7% |
These results build on what was already an impressive Phase 2 dataset. In the 2023 NEJM Phase 2 trial (NCT04881760; Jastreboff et al.), retatrutide demonstrated mean weight loss of approximately 22.8% at 8mg and 24.2% at 12mg over 48 weeks. At the 8mg dose, 100% of participants achieved at least 5% weight loss, and up to 70% achieved 20% or greater weight reduction. The Phase 3 TRIUMPH-4 data confirms that these early signals were not an artifact of trial design — they reflect a genuinely differentiated mechanism of action.
Understanding why retatrutide performs at this level requires understanding what makes it mechanistically distinct. Retatrutide is a triple agonist — it simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This combination is sometimes called triple G in patient communities, reflecting the three receptor targets. No currently approved obesity medication acts on all three pathways simultaneously.
Each receptor contributes something different to the metabolic response. GLP-1 receptor activation reduces appetite and slows gastric emptying, helping to quiet what many patients describe as food noise — the persistent, intrusive preoccupation with eating that makes caloric restriction so difficult. GIP receptor activation enhances insulin sensitivity and may further support appetite regulation. Glucagon receptor activation drives increased energy expenditure and promotes fat mobilization, particularly from the liver.
The clinical consequence of engaging all three pathways is reflected in the cardiometabolic data from the Phase 2 trial. At 24 weeks, the 12mg dose produced a 34.0% reduction in fasting triglycerides compared to -3.1% on placebo. Total cholesterol fell by 17.3% at 12mg, and LDL cholesterol declined by 15.6–16.9% at 8mg. Quality-of-life scores on the SF-36v2 improved across all active dose groups at week 48. These are not trivial numbers — they suggest that retatrutide's effects extend well beyond the scale.
The broader scientific community has taken notice. According to a recent report covered by AP News, Peptides TIL has officially added retatrutide to its public analytical repository in direct response to the scientific momentum surrounding multi-receptor metabolic research. The coverage describes this decision as a response to the "extraordinary scientific momentum" surrounding Phase 3 trials — a phrase that accurately captures the current state of the field. When analytical and research infrastructure organizations begin cataloging a compound in anticipation of its clinical trajectory, it signals a meaningful shift in scientific confidence.
The tolerability profile also deserves honest discussion. Gastrointestinal side effects — nausea, diarrhea, and vomiting — were the most commonly reported adverse events in Phase 2, and they followed a predictable, dose-dependent pattern that peaked during the titration phase. This is consistent with what is observed across the GLP-1 class broadly, and the structured titration schedule used in TRIUMPH-4 was designed specifically to mitigate this burden. Dysesthesia at higher doses is a signal that distinguishes retatrutide from other agents and warrants ongoing attention in the full Phase 3 publication.
This is the question most patients are asking — and it requires a precise, honest answer. As of April 2026, Eli Lilly has not yet filed a New Drug Application (NDA) with the FDA for retatrutide, and no FDA approval timeline has been publicly confirmed. The peer-reviewed Phase 3 publication from TRIUMPH-4 is also pending. The regulatory pathway from positive Phase 3 data to FDA approval typically involves NDA submission, FDA review (standard review is approximately 12 months; priority review approximately 6 months), and potential advisory committee evaluation. No promises about timing can be made.
What is clear is that the scientific foundation is unusually strong. A mean weight loss of 28.7% in a Phase 3 trial, combined with robust cardiometabolic improvements in Phase 2, positions retatrutide as a potential landmark advance in obesity pharmacotherapy. For patients who have not achieved sufficient results with existing approved agents, or who are seeking information about emerging options, staying informed is a reasonable and proactive step.
The Phase 2 trial did exclude individuals with type 2 diabetes, those with a BMI above 50, and those with prior GLP-1 receptor agonist use — eligibility criteria for any future approved indication will be determined through the regulatory process and final labeling.
For patients tracking the retatrutide pipeline, glp3md.com provides ongoing updates as clinical and regulatory developments occur. Joining the waitlist at https://www.glp3md.com is a way to stay at the front of emerging information as the field evolves. Please note: the waitlist is for informational purposes only. Retatrutide is not FDA-approved, and joining the waitlist does not constitute a promise, guarantee, or implication that any medication, treatment, or prescription will be provided. The science is advancing rapidly — being informed is the first step.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.